Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St.
Hims & Hers Health (HIMS) has been in the spotlight after renewing its partnership with Novo Nordisk to offer Novo’s weight loss drugs exclusively, while discontinuing its own competing products and limiting compounded versions.
See our latest analysis for Hims & Hers Health.
At a share price of $22.46, Hims & Hers has had a sharp 43.7% 1 month share price return but a 32.8% decline year to date. The 3 year total shareholder return of 135.4% contrasts with a 40.0% 1 year total shareholder loss, suggesting momentum has recently cooled after a strong multi year run.
If this weight loss story has your attention, it could be a useful moment to scan other healthcare names that blend medicine and technology using our screener for 36 healthcare AI stocks
With Hims & Hers trading at US$22.46, showing an intrinsic discount of around 61% and only a small gap to the average analyst target, you have to ask: is there still a buying opportunity here, or is the market already pricing in future growth?
According to the most followed narrative on Hims & Hers Health, the fair value of $86.09 sits well above the last close at $22.46. This puts a strong spotlight on how the business model and growth assumptions might be driving that gap.
Hims & Hers Health isn’t a telehealth gimmick or a GLP-1 hype stock, it’s quietly becoming the top-of-funnel infrastructure layer for healthcare in the United States. It is executing a strategy similar to Amazon, Spotify, and Costco, deliver more value per dollar spent, reinvest scale advantages, and win via customer-centric efficiency.
Want to see what kind of revenue growth, margin profile, and future profit multiple the narrative is betting on here? The assumptions backing that $86.09 figure lean heavily on compounding earnings power, richer unit economics from personalisation, and platform scale that treats healthcare more like a subscription utility rather than a one off doctor visit.
Result: Fair Value of $86.09 (UNDERVALUED)
Have a read of the narrative in full and understand what’s behind the forecasts.
However, that bullish story could be challenged if regulatory scrutiny around GLP-1 prescribing tightens further, or if larger healthcare and tech players ramp up direct competition.
Find out about the key risks to this Hims & Hers Health narrative.
If this mix of optimism and concern feels familiar, it is a good time to review the underlying data and form your own view quickly and independently, starting with 3 key rewards and 3 important warning signs.
If Hims & Hers has sharpened your interest, this is the moment to widen the net and spot other opportunities before the crowd catches up.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include HIMS.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com